Medicine:Sanofi–Translate Bio COVID-19 vaccine
| Vaccine description | |
|---|---|
| Target disease | SARS-CoV-2 |
| Type | mrna |
| Clinical data | |
| Other names | MRT5500, VAW00001 |
| Routes of administration | Intramuscular |
| Legal status | |
| Legal status |
|
The Sanofi–Translate Bio COVID-19 vaccine, also known as MRT5500 or VAW00001, was a COVID-19 vaccine candidate developed by Sanofi Pasteur and Translate Bio.[2][3] The development was stopped in September 2021.[4]
History
In June 2020, Sanofi, after lagging behind its competitors, "accelerated" the development of the vaccine via the smaller biotech firm Translate Bio, with a United States dollar $425 million partnership.[5]
Development of the vaccine halted in September 2021, with Sanofi citing the difficulty of running placebo-controlled studies with other mRNA vaccines (such as Pfizer's and Moderna's) already on the market. Despite this, the company reported "promising results" in its initial trials.[4]Sanofi has continued testing its recombinant protein vaccine, developed collaboratively with GlaxoSmithKline, to serve as a booster dose for other COVID-19 vaccines.[4]
References
- ↑ "Sanofi stops development of Covid vaccine based on mRNA technology". Financial Times. 28 September 2021. https://www.ft.com/content/22ec6b9f-d007-41a9-8ab9-a76d17c73a3f.
- ↑ "Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate". Sanofi. 12 March 2021. https://www.sanofi.com/en/media-room/press-releases/2021/2021-03-12-07-00-00-2191846.
- ↑ "Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older (VAW00001)". United States National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT04798027.
- ↑ 4.0 4.1 4.2 "Sanofi drops plans for messenger RNA vaccine against virus". Associated Press. 28 September 2021. https://apnews.com/article/coronavirus-pandemic-technology-business-public-health-coronavirus-vaccine-aeb851722ad9f876395cf8e5af4aea5a.
- ↑ "Sanofi, a straggler in the Covid-19 vaccine race, accelerates its plans". STAT. 23 June 2020. https://www.statnews.com/2020/06/23/sanofi-a-straggler-in-the-covid-19-vaccine-race-accelerates-its-plans/.
External links
 |
